top of page
  • Patient Education: Video

NCI National Cancer Institute: Manufacturing CAR T Cells to Accelerate Cancer Immunotherapy Research

Updated: Apr 7, 2022

NCI National Cancer Institute: Manufacturing CAR T Cells to Accelerate Cancer Immunotherapy Research

Immunotherapy CART Multiple Myeloma

Manufacturing CAR T Cells to Accelerate Cancer Immunotherapy Research


An example of CART Cell therapy approved by FDA to treat relapsed & refractory Multiple Myeloma is

Idecabtagene Vicleucel ( Abecma)


Clinical trials with Abecma




Posts Archive
bottom of page